decreases from 2.5% of total body weight in young people to about 1.6% in the nonagenarian population, and several morphological changes with aging indicate that the liver cells in advanced old age are in a hyperfunctioning state, possibly trying to compensate for the decline in total cell number. 4 However, it has been suggested that aging has a limited effect on liver functions but more on its response to extrahepatic factors, 5 disease states or increased metabolic demands to which elderly people may have an impaired ability to respond. 4 Atheromatosis usually affects the celiac trunk in old donors but, although this happens rarely, when atheroma occurs distally at the level of the right hepatic artery or at the bifurcation of the gastroduodenal and the common hepatic artery, the liver graft must be discarded for LT.
From that time, we have continued applying the same criteria, but in recent years we have added other conditions such as implanting the octogenarian livers into recipients without Hepatitis C virus (HCV) cirrhosis and model for end-stage liver disease scores lower than 20 who could tolerate well a probable transient graft dysfunction. 2 As we have seen in this short experience, it is possible that an octogenarian liver graft can reach the centennial age after transplant while the recipient maintains a normal liver function and a good quality of life if a good donor selection is done, and recipients with HCV cirrhosis or advanced liver disease are excluded, but at present, with the current introduction of new anti-HCV drugs, we are also using these older donors in HCV recipients to decrease the waiting list mortality. However, further investigations are needed to demonstrate good results using octogenarian liver donors in HCV recipients. coworkers published the inverse association of TTV load with rejection after kidney transplantation. 3 We report similar findings in 39 patients (median age, 60 years [range, 1-73 years]; male subjects, 59%) enrolled in the Swiss Transplant Cohort Study after orthotopic liver transplantation (OLT) for liver disease of viral (33%), toxic (10%), or other (57%) origins.
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We measured TTV-DNA levels by real-time polymerase chain reaction 4 at time of transplantation and at 6 and 12 months posttransplant for the 19 patients with available serum samples. Seventy-four healthy subjects served as controls (HC). TTV-DNA was detectable (detection limit 25 viral copies/mL of plasma) in 29 (74%) of 39 patients at transplantation, a prevalence similar to the one observed in controls (51/74, 69%; P = 0.8035; χ 2 test). However, median TTV-DNA levels were significantly higher in OLT recipients (median, 4.54 Â 10 3 copies/mL; range, 25-1.2 Â 10 8 ) compared with controls (median, 1.7 Â 10 2 copies/mL; range, 25-5.4 Â 10 4 ; P = 0.0014, Mann-Whitney U test) ( Figure 1A 
; range, 25-1.7 Â 10 7 at 12 months) ( Figure 1A ).
We further assessed the relationship between TTV-loads at transplantation with the risk of biopsy-proven acute cellular graft rejection (Rejection Activity Index score ≥3 or ≥2 with significant necrosis) during the first year after transplantation. Interestingly, 1-year cumulative incidence of rejection in OLT recipients with detectable TTV-DNA plasma levels at transplantation was significantly lower (21% [95% confidence interval (CI), 8%-37%]) than in patients with undetectable TTV titers (70% [95% CI, 28%-90%]; P = 0.0042, Gray test; Figure 1B ).
To account for factors with potential impact on TTV replication and rejection such as age, gender, HBV, HCV, and HIV serostatus, underlying disease, number of immunosuppressive drugs used, hepatic encephalopathy, and presence of human leukocyte antigen donor-specific antibodies, we performed a multivariate analysis using FineGray proportional hazard regression for competing events. This analysis confirmed the reduced 1-year cumulative incidence of rejection in patients with detectable TTV titers at time of transplantation (HR, 9 Â 10 −3 [95% CI, 1 Â 10
to 9.2 Â 10 −2
; P = 0.00008]). Our results in OLT recipients are in agreement with those reported by Schiemann et al for kidney transplant recipients and reinforce the results of De Vlaminck and coworkers who found that anellovirus levels in heart and lung transplant recipients with acute rejection episodes were lower than in nonrejecting patients. 5 It is tempting to speculate that a higher immunocompetence in TTV-negative patients at transplantation could be responsible for the higher incidence of rejection episodes observed during the first year after transplantation.
Obviously, our study presents several limitations. First, because serological testing for TTV is currently unavailable, we cannot exclude that some patients are TTV-negative simply because they never have been infected. However, we do believe that the high prevalence of TTV in the population makes this unlikely. Second, the study remains somewhat incomplete because the lack of posttransplant serum samples precluded the analysis of a potential prognostic value of TTV titers after OLT. Larger prospective studies with more patients than in our retrospective pilot study are needed to assess whether monitoring TTV titers could help identifying patients at higher risk of acute rejection after OLT. FIGURE 1. TTV load kinetics and impact on the frequency of rejection episodes after OLT. A, TTV-DNA titers in OLT recipients (filled dots) compared with healthy controls (HC, white dots). Gray filled dots identify patients analyzed at time of transplantation (M0) exclusively. Black filled dots identify patients analyzed at time of transplantation (M0) and 6 (M6) and 12 months (M12) after transplantation. Comparison was performed using the Mann-Whitney U test, and P values are indicated when significant (P < 0.05). B, One-year biopsy-proven acute rejection cumulative incidence in patients displaying detectable (gray line) and undetectable (black line) TTV-DNA at transplantation. Cumulative incidence of rejection analysis was performed using Gray test with death without rejection as a competing event.
